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Purpose: Bone is the most frequent site of metastasis among breast cancer patients. 
We investigated prognostic factors affecting survival following bone-only metasta-
sis in breast cancer patients. Materials and Methods: The medical records of 
breast cancer patients who were treated and followed at Gangnam Severance Hospi-
tal retrospectively reviewed to identify patients with bone-only metastasis. Results: 
The median time from the diagnosis of bone-only metastasis to the last follow-up or 
death was 55.2 [95% confidence interval (CI), 38.6-71.9] months. The Kaplan-Mei-
er overall survival estimate at 10 years for all patients was 34.9%. In the multivari-
ate Cox regression model, bisphosphonate treatment [hazard ratio=0.18; 95% CI, 
0.07-0.43], estrogen receptor positivity (hazard ratio=0.51; 95% CI, 0.28-0.94), and 
solitary bone metastasis (hazard ratio=0.32; 95% CI, 0.14-0.72) were significantly 
associated with longer overall survival in the bone-only recurrence group. Among 
the treatment modalities, only bisphosphonate treatment was identified as a signifi-
cant prognostic factor. Conclusion: Identifying the factors influencing breast cancer 
mortality after bone-only metastasis will help clarify the clinical course and improve 
the treatment outcome for patients with breast cancer and bone-only metastasis. 
Bisphosphonates, as a significant prognostic factor, warrant further investigation.
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INTRODUCTION
Bone is the most frequent site of metastasis among patients with breast cancer, and 
70% of breast cancer patients experience distant bone relapse.1 Factors affecting 
bone metastasis at the first distant relapse in breast cancer are well established. Tu-
mors with estrogen (ER) and progesterone receptor positivity, a low or intermedi-
ate histologic grade, and a low mitotic rate have a greater propensity to metastasize 
to bone than to the viscera.2,3 Breast cancer metastases with synchronous multiple 
sites of recurrence are common,4 and systemic metastasis limited to bone are less 
frequent. Bone-only metastasis has been reported to occur in 17-37% of patients 
with distant metastasis.5-7   
Distant metastasis confined to the skeletal system has a more favorable progno-
sis than other types of distant metastasis or multiple metastases to bone and the 
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ment. Among the identified patients with bone metastases 
(n=311), patients with bone metastasis accompanied by syn-
chronous distant metastasis to other organs were excluded 
(n=192). Patients with progression to other distant metasta-
sis within 6 months of the diagnosis of bone-only metasta-
sis (n=9) were also excluded. Bone metastasis was diag-
nosed based on imaging studies using a bone scan and/or 
positron emission tomography/computed tomography and/
or magnetic resonance imaging. We reviewed medical re-
cords for any discrepancies in the information and patho-
logic data of these patients. We also summarized the clini-
copathologic characteristics of the patients and the details 
of various treatments. The Institutional Review Board ap-
proved this study, and the need for informed consent was 
waived because of the retrospective design.
Treatment modalities
Medical information regarding the treatment modalities for 
bone metastasis was obtained via chart review. We defined 
the treatments for bone metastasis as any kind of treatments 
performed from the time of diagnosis of bone metastasis to 
the time of development of other systemic metastasis or 
mortality. Previous chemotherapy, endocrine therapy, and 
radiotherapy before the diagnosis of bone-only metastasis 
were excluded. According to the number of utilized chemo-
therapy regimens, patients who received chemotherapy were 
categorized into single-treated and heavily-treated groups. 
The single-treated group included patients who received 
treatment with a single cytotoxic regimen during the study 
period, and the heavily-treated group included patients who 
received two or more chemotherapy regimens as a result of 
metastatic bone disease progression. Bisphosphonate treat-
ment was defined as the persistent administration of bisphos-
phonate for more than 2 months according to a previous re-
port.14 Bisphosphonates were administered every 4 weeks 
intravenously. Patients treated with bisphosphonate re-
ceived zoledronic acid or pamidronate.
Statistical analysis 
The nonparametric Wilcoxon rank sum significance test 
was applied to compare the ages and tumor sizes of patients 
at the time of diagnosis between the de novo and recurrence 
groups. The significance of differences between the two 
groups for categorical variables was tested using the χ2 test 
or Fisher’s exact test. The primary endpoint of this study 
was overall survival (OS) since the diagnosis of bone-only 
metastasis. OS was defined from the time of the first detec-
viscera.7-9 Other investigators reported that the median sur-
vival of patients with bone-only metastasis was 24-54 
months.7-10 Many factors associated with overall prognosis 
at early breast cancer diagnosis retain prognostic signifi-
cance for survival following the first diagnosis of metastatic 
breast cancer.11-13 As a result, favorable tumor characteris-
tics of the primary tumor explain the modest prognosis of 
women with bone-only metastasis.2,3
Many physicians have sought to establish the optimal 
treatment strategy for women with bone metastasis. Among 
the treatment modalities, endocrine therapy, chemotherapy, 
external radiotherapy, and bisphosphonate therapy are avail-
able therapeutic options for these patients. It is unknown 
which treatment approach (endocrine therapy alone, che-
motherapy alone, combinatory therapy) prolongs survival 
in patients with bone-only metastasis. Moreover, little evi-
dence has been provided regarding the prognostic factors 
that may predict better or worse outcomes among patients 
with bone-only metastases. 
Niikura, et al.10 compared the treatment outcomes of en-
docrine therapy or chemotherapy with that of combination 
therapy (chemotherapy followed by endocrine therapy, or 
endocrine therapy combined with molecular-targeted thera-
py) among patients with breast cancer with bone-only me-
tastasis, but the optimal treatment option was not elucidated 
tangibly in that study.
The primary goal of the current study was to identify prog-
nostic factors affecting survival after bone-only metastasis 
with clinicopathologic factors including therapeutic modal-
ities such as endocrine therapy, radiotherapy, chemothera-
py, and bisphosphonate treatment.
MATERIALS AND METHODS
　　　
Patients 
A prospectively maintained database of breast cancer pa-
tients treated at Gangnam Severance Hospital was used to 
identify patients with bone-only metastasis diagnosed be-
tween January 1991 and June 2011. Patients with bone-on-
ly metastasis were stratified into two groups based on the 
timing of bone metastasis. The de novo group consisted of 
the patients who had bone-only metastasis detected during 
the initial diagnosis of breast cancer. The recurrence group 
consisted of the patients who developed bone-only metasta-
sis after completing curative management of the primary 
breast tumor and neoadjuvant and/or adjuvant systemic treat-
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treatement was subsequently changed to zoledronic acid. 
Although we utilized an inclusion criterion of persistent use 
of bisphosphonates for more than 2 months, all patients 
treated with bisphosphonates received the agents for a con-
tinuous period of at least 12 months. 
By the end of the follow-up period, 56 patients (50.9%) 
had died, and the OS at 10 years was 34.9% (Fig. 1). The 
median time from the initial primary breast cancer diagnosis 
to the last follow-up or death, the median time from the ini-
tial primary tumor diagnosis to the diagnosis of bone metas-
tasis, and the median OS after the diagnosis of bone-only 
metastasis were 75.0 [95% confidence interval (CI), 57.2-
92.8], 31.0 (95% CI, 20.7-41.2), and 55.2 (95% CI, 38.6-
71.9) months, respectively. The Kaplan-Meier overall sur-
vival at 5 years for patients with de novo bone metastasis was 
higher than that for patients with recurrent bone metastasis 
(60.2% vs. 44.1%); however, a significant difference be-
tween their overall survival was not observed (p=0.136). In 
the univariate analysis of OS after bone-only metastasis, a 
lower number of metastatic lymph nodes (p=0.006), endo-
crine therapy (p=0.022), recurrence-free interval exceeding 2 
years (p<0.001), ER positivity (p=0.027), bisphosphonate 
treatment (p<0.001), and solitary bone metastasis (p<0.001) 
were associated with a better survival outcome (Table 2). 
In the multivariable analysis, patients assigned to the de 
novo group were excluded because their recurrence-free in-
tervals could not be measured. According to the Cox regres-
sion model selected using Akaike Information Criteria, soli-
tary bone metastasis (hazard ratio=0.32, 95% CI, 0.14-0.72), 
ER positivity (hazard ratio=0.51, 95% CI, 0.28-0.94), and 
bisphosphonate treatment (hazard ratio=0.18, 95% CI, 0.07-
0.43) were significantly associated with longer OS after 
bone-only metastasis (Table 3). The Kaplan-Meier plots re-
garding with these significant factors are shown in the Fig. 2. 
In further subgroup analysis focusing on the ER-positive 
patients, bisphosphonate treatment (hazard ratio=0.27, 95% 
CI, 0.10-0.72) and the number of bone metastases (hazard 
ratio=0.14, 95% CI, 0.03-0.58) were again independently 
and significantly associated with breast cancer mortality 
(Table 4). Note that the recurrence-free interval with weak 
statistical significance in Table 3 and 4 improved the AIC; 
thus, it was retained in the final multivariate model. 
DISCUSSION
In the current study, we retrospectively reviewed the clini-
tion of bone metastasis to death or the last follow-up. The 
Kaplan-Meier method was utilized to estimate the OS for 
each categorical variable, and the estimated survival curves 
for different groups were compared using the log-lank test. 
All of the covariates that displayed marginally significant 
associations with OS were introduced into the Cox propor-
tional hazards regression model. According to the Akaike 
Information Criteria (AIC), we determined the covariates 
most significantly associated with mortality while avoiding 
over-parameterization. All statistical analyses were per-
formed using the Statistical Software Package for the Social 
Sciences (SPSS version 18.0 for Windows; SPSS Inc., Chi-
cago, IL, USA) and the R software (http://www.r-projet.org). 
A p-value <0.05 was considered statistically significant.
 
RESULTS
 
In total, 110 breast cancer patients were enrolled in this study, 
including 91 patients in the recurrence group and 19 patients 
in the de novo group. The baseline characteristics of the pa-
tients are summarized in Table 1. The median ages at the 
time of breast cancer diagnosis in the recurrence and de novo 
groups were 43 and 45 years, respectively (p=0.346), the me-
dian ages at the diagnosis of bone metastasis in the two 
groups were 47 and 45 years, respectively (p=0.317), and the 
median tumor size was 3.0 cm in both groups (p=0.671). The 
proportion of patients with advanced node stage was simi-
lar between the two groups (p=0.174), whereas the entire 
de novo group consisted of patients with stage IV disease 
(p<0.001). Regarding the treatment modalities, the propor-
tions of patients who received endocrine therapy and bisphos-
phonate treatment were significantly higher in the de novo 
group than in the recurrence group (p=0.007 and p=0.001, 
respectively). There were no significant differences regard-
ing the other treatment modalities between the two groups.
Among the patients who received chemotherapy for bone 
metastasis (n=99), 86 patients (87%) were in the single-treat-
ed group, and 13 patients (13%) were in the heavy-treated 
group. Among the patients who received endocrine therapy 
(n=45), 18 (40.0%) received tamoxifen, 25 (56%) received 
an aromatase inhibitor, and 2 (4%) received both agents. 
Among the patients treated with chemotherapy or endo-
crine therapy, 37 received both treatments. Among the pa-
tients managed with bisphosphonates (n=45), 41 (91%) re-
ceived zoledronic acid, 3 (7%) received pamidronate, and 1 
(2%) initially received pamidronate, although this patient’s 
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patients with other types of distant metastasis.7-9 This favor-
able survival outcome of the patients with bone-only me-
tastasis motivated us to conduct this investigation and facil-
itated the attempt to seek a treatment strategy best suited to 
these patients. Advances in radiotherapy, chemotherapy, 
and bisphosphonate treatment may have contributed to the 
improved management of metastatic bone disease.10   
cal features and treatment outcomes of breast cancer pa-
tients with bone-only metastases. This single-institution 
study of Korean patients analyzed the clinical features, sur-
vival, and prognostic factors of bone-only metastasis. The 
median OS following bone-only metastasis in our cohort 
was 55.2 months, and the survival time of the patients with 
bone-only metastasis appeared modest compared to that of 
Table 1. Patient Characteristics According to the Timing of Bone Metastasis Diagnosis
Characteristics
Recurrence* 
(n=91)
De Novo bone metastasis* 
(n=19)
p value‡
Median age† at initial diagnosis, yrs        43 (23-73)       45 (27-67)    0.346§
Median age† at diagnosis of bone-only 
  metastasis, yrs
      47 (27-79)       45 (27-67)    0.317§
Median tumor size,† cm             3 (1.0-13.0)         3.0 (2.0-10.0)    0.671§
Number of metastatic LN   0.085
    Negative (n=25) 21 (23)   4 (21)
    1-3 (n=43) 31 (34) 12 (63)
    4-9 (n=21) 20 (22) 1 (5)
    ≥10 (n=21) 19 (21)   2 (11)
TNM stage <0.001
    I (n=10) 10 (11) 0 (0)
    II (n=38) 38 (42) 0 (0)
    III (n=43) 43 (47) 0 (0)
    IV (n=19) 0 (0)   19 (100)
Estrogen receptor status    0.789||
    Positive (n=77) 63 (69) 14 (74)
    Negative (n=33) 28 (31)   5 (26)
Histologic grade¶    0.231||
    I (n=25) 23 (25)   2 (10)
    II, III (n=83) 66 (73) 17 (90)
Number of bone metastasis   0.770
    Single (n=32) 27 (42)   5 (26)
    Multiple (n=78) 64 (58) 14 (74)
Chemotherapy   0.216
    Single-treated (n=86) 71 (78) 15 (96)
    Heavily-treated (n=13)  9 (12)   4 (21)
    No receipt (n=11) 11 (23) 0 (0)
Endocrine therapy   0.007
    Receipt (n=45) 32 (35) 13 (68)
    No receipt (n=65) 59 (65)   6 (32)
Radiotherapy   0.110
    Receipt (n=80) 69 (76) 11 (58)
    No receipt (n=30) 22 (24)   8 (42)
Bisphosphonate therapy    0.002||
    Receipt (n=45) 31 (34) 14 (74)
    No receipt (n=65) 60 (66)   5 (26)
n, number; TNM, tumor-node-metastasis; LN, lymph node.
*Values in parentheses are percentages or †ranges.
‡χ2 test, §Mann-Whitney U test, and ||Fisher’s exact test.
¶Information is not available for all of the patients.
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of life for patients with hormone receptor (HR)-positive and 
human epidermal receptor-2-negative patients with bone-
only metastases.9,18 However, endocrine therapy did not 
provide a statistically significant therapeutic effect in our 
study. In our subgroup analysis for the ER-positive patients, 
results regarding endocrine therapy did not change. Howev-
er, the relevance of endocrine therapy as a primary treat-
ment option deserves further investigation.  
Although patients were stratified into two groups accord-
ing to the timing of bone metastasis diagnosis, significant 
differences were not found in the survival analysis of these 
two groups (p=0.136). Despite the slightly better treatment 
outcome in the de novo group, the timing of bone metastasis 
might not be a significant prognostic factor for OS among 
patients with bone-only metastasis.
The prognostic factors identified in our study include the 
number of bone metastases (hazard ratio=0.32) (Table 3). 
This finding was equivalent to the report of Koizumi, et 
al.12 that solitary bone metastasis is an independent prog-
nostic factor in patients with skeletal metastasis.      
According to previous studies, ER status and recurrence-
free interval were commonly known to influence survival 
time following bone metastasis.3,9,13,15 The positive influ-
ence of the ER status of the primary tumor on the survival 
time following bone metastasis observed in other studies 
was also confirmed in our results.3,12 This finding that ER 
positivity was associated with a better survival following 
the diagnosis of bone metastasis (hazard ratio=0.51) (Table 
3) is in agreement with other reports that factors associated 
with the prognosis at diagnosis retain prognostic signifi-
cance for survival after the diagnosis of metastatic breast 
cancer.10,12,16,17   
Because a higher proportion of ER-positive patients de-
veloped bone-only metastasis and because of the influence 
of ER status on prognosis, adjuvant endocrine therapy may 
have an important role in the management of patients with 
bone-only metastasis. Previous reports recommended endo-
crine therapy to mitigate symptoms, minimize serious com-
plications, and extend survival while preserving the quality 
Fig. 1. Kaplan-Meier plot showing OS for all patients. OS, overall survival.
Table 2. Univariate Analysis of Prognostic Factors Affecting 
Survival after Bone Metastasis
Characteristics
Number of 
patients
p value*
Age 0.498
    ≥35 yrs 88
    <35 yrs 22
Tumor size 0.997
    ≥2 cm 86
    <2 cm 24
Number of metastatic LN 0.006
    Negative 25
    1-3 43
    4-9 32
    ≥10 21
Estrogen receptor status 0.027
    Positive 33
    Negative 77
Histologic grade 0.947
    I 25
    II, III 81
Recurrence-free interval (RFI) <0.001
    RFI <2 yrs 26
    RFI ≥2 yrs 65
Number of bone metastasis <0.001
    Single 32
    Multiple 78
Chemotherapy 0.169
    Single-treated 86
    Heavily-treated 13
    No receipt 11
Endocrine therapy 0.022
    Receipt 45
    No receipt 65
Radiotherapy 0.599
    Receipt 80
    No receipt 30
Bisphosphonate therapy <0.001
    Receipt 45
    No receipt 65
LN, lymph node.
*Log-rank test.
0.0
0.2
0.4
0.6
0.8
1.0
OS
0 2 4 6 8 10 12 14
Years after bone metastasis
Overall survival rate at 10 years: 34.9%
No. at risk (Cum. no. of events)
All patients 110 (0)   89 (17)   47 (44)   26 (53)   17 (55)   7 (56)   4 (56)   4 (56)
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that the administration of bisphosphonates including zole-
dronic acid and pamidronate may provide a survival benefit 
in patients with metastatic breast cancer with HR-negative 
tumors, whereas it did not enhance survival in a recent study 
on the antitumor effect of zoledronic acid in breast cancer 
patients with bone-only metastasis.14
In our results, bisphosphonate treatment was the most 
significant prognostic factor of OS after bone-only metasta-
sis. In this study, 97% of bisphosphonate-treated women re-
ceived zoledronic acid, which is much more potent than 
other bisphosphonates.:27,28 This finding was suggestive of a 
promising therapeutic benefit of bisphosphonate treatment. 
Moreover, in our study population, median age at the diag-
nosis of bone-only metastasis was 47.0 years-old, which be-
longs to the perimenopausal period. Among the population, 
99 patients (90.0%) received chemotherapy, which may have 
induced a transient or permanent amenorrhea. With specula-
tion from this background, a large number of the patients 
might have been in postmenopausal status, which is associat-
ed with the improvement of treatment outcome of zoledron-
ic acid.36-38  
Another reason could be that most patients treated with 
bisphosphonates receive this treatment for at least 12 months, 
and the duration of bisphosphonate use in this study was 
relatively longer than that reported previously. These find-
ings provided clinical evidences for a favorable therapeutic 
effect of bisphosphonates on the prognosis of breast cancer 
patients with bone-only metastasis in addition to their ancil-
lary role in supportive care to control skeletal-related events. 
Nevertheless, there might be selection bias with regard to 
the patients who received bisphosphonate treatment. Only 
The recurrence-free interval was also associated with the 
survival time of the patients with bone-only metastasis. A re-
currence-free interval of less than 2 years suggested worse 
prognosis19 and increased the mortality rate in patients with 
breast cancer.20 In our results, the recurrence-free interval 
retained its clinical significance, and it was verified as a 
prognostic factor for patients with bone-only metastasis.
Among the treatment modalities, only bisphosphonate 
treatment was identified as a significant prognostic factor in 
our multivariate survival analysis (hazard ratio=0.18) (Table 
3). Our results revealed a significantly better OS for patients 
who received bisphosphonate treatment than for those who 
did not receive bisphosphonate treatment (Fig. 2A). Bisphos-
phonates are commonly used in patients with breast cancer 
to reduce the incidence of skeletal-related events in meta-
static disease and to minimize bone loss.21-25 Zoledronic 
acid, a third-generation nitrogen-containing bisphosphonate, 
reduces the incidence of skeletal complications in breast 
cancer patients with confirmed bone metastases.26-28 Several 
studies suggested that zoledronic acid promotes antiangio-
genesis and apoptosis29-31 and has synergistic antitumor ef-
fects with chemotherapy in preclinical settings.31,32
It is still controversial whether bisphosphonates improve 
treatment outcome.33-36 Although several large trials of zole-
dronic acid have supported prolonged recurrence-free sur-
vival in postmenopausal or otherwise estrogen-depleted 
women with early breast cancer,36-38 adjuvant treatment with 
zoledronic acid was not demonstrated to improve the prog-
nosis of breast cancer patients.14 In the management of met-
astatic breast cancer, bisphosphonate administration also 
did not provide a survival benefit.21-25 Park, et al.39 reported 
Table 3. Prognostic Factors of Breast Cancer Mortality in the Bone-Only Recurrence Group (n=91)
Characteristics p value Hazard ratio (95% CI)
Estrogen receptor status   0.031
    Negative Reference
    Positive 0.51 (0.28-0.94)
Recurrence-free interval (RFI)   0.054  
    RFI <2 yrs  Reference
    RFI ≥2 yrs  0.56 (0.31-1.01)
Number of bone 
  metastasis
  0.006  
    Multiple  Reference
    Single  0.32 (0.14-0.72)
Bisphosphonate therapy <0.001  
    No receipt  Reference
    Receipt  0.18 (0.07-0.43)
CI, confidence interval.
Cox proportional hazards regression model selected using Akaike Information Criteria in stepwise selection; hazard ratios are adjusted for all of the factors 
listed in the table.
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Table 4. Prognostic Factors of Breast Cancer Mortality in the ER-Positive Group (n=63)
Characteristics p value Hazard ratio (95% CI)
Recurrence-free interval (RFI) 0.082
    RFI <2 yrs Reference
    RFI ≥2 yrs  0.52 (0.25-1.09)
Number of bone metastasis 0.006
    Multiple Reference
    Single 0.14 (0.03-0.58)
Bisphosphonate therapy 0.009
    No receipt Reference
    Receipt 0.27 (0.10-0.72)
ER, estrogen; CI, confidence interval.
Cox proportional hazards regression model selected using Akaike Information Criteria in stepwise selection; hazard ratios are adjusted for all of the factors 
listed in the table.
Fig. 2. Kaplan-Meier plot showing OS stratified by (A) bisphosphonate treatment (log-rank test, p<0.001) (B) ER status (log-rank test, p=0.027) (C) the recur-
rence-free interval (log-rank test, p<0.001), and (D) the number of bone metastases (log-rank test, p<0.001). OS, overall survival; ER, estrogen; RFI, recur-
rence-free interval.
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No. at risk (Cum. no. of events)
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Positive 
No. at risk (Cum. no. of events)
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No. at risk (Cum. no. of events)
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No. at risk (Cum. no. of events)
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Receipt 
33 (0)
26 (0)
78 (0)
65 (0)
77 (0)
66 (0)
32 (0)
45 (0)
22 (9)
21 (5)
61 (16)
48 (17)
66 (8)
54 (9)
27 (1)
41 (0)
  9 (19)
  6 (17)
29 (38)
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38 (25)
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18 (6)
26 (3)
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D
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its retrospective and single-institution design, possibly lead-
ing to selection and referral bias. As a result, randomizations 
to different treatments were not performed. Each treatment 
modality was not systemized, and different types of drugs, 
doses, and schedules were used. The small study popula-
tion is another limitation.
In conclusion, our results revealed a relatively good prog-
nosis of bone-only metastasis, and we identified significant 
prognostic factors for survival following bone-only metas-
patients with good performance status or anticipated better 
survival were likely to receive bisphosphonate treatment. 
However, in the recurrence group used for multivariate anal-
ysis, there was no significant difference between two sub-
groups stratified by bisphosphonate therapy (Supplementary 
Table 1). This suggests that characteristics of the bisphospho-
nate treated-group are not much different from those of the 
not-treated group.
Additionally, the limitations of the present study include 
Supplementary Table 1. Patient Characteristics According to Bisphosphonate Treatment in the Recurrence Group (n=91)
Characteristics
Bisphosphonate-treated*
 (n=31)
Bisphosphonate not-treated* 
(n=60)
p value‡
Median age† at initial diagnosis, yrs        45 (23-59)      43 (26-73)  0.373§
Median age† at diagnosis of bone-only 
  metastasis, yrs
      49 (30-65)      47 (27-79)  0.725§
Median tumor size,† cm    3 (1-9)   3.1 (1-13)  0.187§
Number of metastatic LN 0.562
    Negative (n=21)   5 (16) 16 (27)
    1-3 (n=31) 13 (42) 18 (30)
    4-9 (n=20)   6 (19) 14 (23)
    ≥10 (n=19)   7 (23) 12 (20)
TNM stage 0.586
    I (n=10) 2 (6)   8 (13)
    II (n=38) 13 (42) 25 (42)
    III (n=43) 16 (52) 27 (45)
Estrogen receptor status  0.816||
    Positive (n=63) 21 (68) 42 (70)
    Negative (n=28) 10 (32) 18 (30)
Histologic grade¶  0.644||
    I (n=23)   8 (25) 15 (25)
    II, III (n=64) 22 (75) 42 (75)
Number of bone metastasis 0.227
    Single (n=27) 12 (39) 15 (25)
    Multiple (n=64) 19 (61) 45 (75)
Recurrence-free interval (RFI) 0.222
    RFI <2 yrs (n=26)   6 (19) 20 (33)
    RFI ≥2 yrs (n=65) 25 (81) 40 (67)
Chemotherapy 0.262
    Single-treated (n=78) 24 (77) 54 (90)
    Heavily-treated (n=9)   5 (16) 4 (7)
    No receipt (n=4) 2 (7) 2 (3)
Endocrine therapy 0.361
    Receipt (n=32) 13 (42) 19 (32)
    No receipt (n=59) 18 (58) 41 (68)
Radiotherapy 0.208
    Receipt (n=69) 21 (68) 48 (80)
    No receipt (n=22) 10 (32) 12 (20)
n, number; TNM, tumor-node-metastasis; LN, lymph node.
*Values in parentheses are percentages or †ranges.
‡χ2 test, §Mann-Whitney U test, and ||Fisher’s exact test.
¶Information is not available for all of the patients.
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tasis in patients with breast cancer. Despite the lack of a 
proven treatment option, diverse treatment modalities were 
observed to positively affect the prognosis of bone-only me-
tastasis, and effort to develop an appropriate treatment strat-
egy should be continued. Bisphosphonates identified as a 
significant prognostic factor in our study warrant further in-
vestigation.
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